|
|
Caitlyn |
|
Harvey |
|
Vice President, Head of CMC |
Convergent Therapeutics, Inc. |
https://proventainternational.com/wp-content/uploads/2025/04/Caitlyn-Harvey.jpg |
|
|
|
Claire |
|
Elizabeth Smith |
|
Partner |
SpringTide Ventures |
https://proventainternational.com/wp-content/uploads/2025/02/Claire-Elizabeth-Smith.jpg |
Claire is a partner at SpringTide and has spent her career focused at the intersection of healthcare, life sciences, and business. Prior to SpringTide, she was an investor at Meridian Street Capital, where she focused on seed-stage health tech, and Anterra Capital, where she focused on the intersection of biotech and agriculture while launching several animal health startups. Previously, she served as the Chief of Staff at Crestovo, a microbiome therapeutics startup acquired by Finch Therapeutics. She began her career at ClearView Healthcare Partners, a boutique life sciences consultancy, where she advised pharma and biotech clients on a variety of growth strategy topics. Claire holds bachelor’s degrees in biological engineering and management science from MIT.She is on the board of Leash Labs and serves as a board observer at IgniteData and Paterna Biosciences. |
|
|
Doug |
|
Zingale |
|
Managing Partner |
Blue Goose Capital |
https://proventainternational.com/wp-content/uploads/2025/05/Doug-Zingale.jpg |
|
|
|
David |
|
Sherris |
|
President and CEO |
Attivare Therapeutics |
https://proventainternational.com/wp-content/uploads/2020/01/David-Sherris-1.jpg |
David Sherris, Ph.D., President, CEO and Chairman of the Board of Directors of Attivare Therapeutics has over 30 years of experience in translational medicine, encompassing basic research, pharmaceutics, and diagnostics. As a successful serial entrepreneur, he has developed biotechnology companies from the ground up, devising corporate strategy, implementing programs, and guiding companies through funding and acquisitions, achieving multiple exits. Dr. Sherris prides himself on being a hands-on CEO, entrepreneur, business development officer, drug developer, and scientist, rather than merely a delegator. He has worked with venture capital, investment banks, and angel investors, advising and raising well over $100 million. |
|
|
Gopi |
|
Vudathala |
|
Global Head, Regulatory Affairs CMC |
Incyte Corporation |
https://proventainternational.com/wp-content/uploads/2022/08/Gopi-Vudathala-1.jpg |
Dr. Vudathala, Ph.D., is currently Global Head, RA CMC at Incyte Corporation. He was Formerly Executive Director of RA CMC at Intarcia Therapeutics, Head of Quality Advocacy at GSK Vaccines and Global Head of Regulatory CMC at Novartis Vaccines. He was also Associate Vice President of Regulatory Affairs CMC at Sanofi-Aventis. He has extensive experience in CMC regulatory strategy for Global Development and Life-Cycle Management Projects and contributed to over 30 NDA and BLA approvals and 60 INDs. Dr. Vudathala has had numerous interactions with global regulators on project related CMC matters as well as on key ICH initiatives. He has published extensively on drug development and regulatory CMC topics. He was on the Regulatory and Quality Advisory Board at the Parenteral Drug Association and a member of the PDA core team on ICHQ12/ Post Approval Changes. |
|
|
Gregory |
|
Papastoitsis |
|
Chief Process and Manufacturing Officer |
Ankyra Therapeutics |
https://proventainternational.com/wp-content/uploads/2025/02/Gregory-Papastoitsis.jpg |
Dr. Gregory Zarbis-Papastoitsis is the Chief Process and Manufacturing Officer at Ankyra Therapeutics, an immune-oncology company, where he is responsible for all CMC activities. Prior to Ankyra, he was the EVP of Process and Manufacturing at Compass Therapeutics where he oversaw all CMC activities for a CD137 agonist, which is currently in Phase 1/2 clinical studies. Before he was the SVP of development and manufacturing at Eleven Biotherapeutics where he worked on an IL-1 inhibitor that reached pivotal clinical studies for Dry Eye Disease, and an anti-IL6 antibody (successful IND), for Macular Edema. Earlier, he was Associate Director of Process and Analytical Development at Syntonix Pharmaceuticals, where he was responsible for the early development of a long-lasting Factor IX (ALPROLIX®). He also worked on the commercial process of HUMIRA® (Abbott/Abbvie), on the purification process of ONTAK® , an IL2-diphtheria toxin fusion protein (Seragen), on the early development of an antibody-toxin conjugate (aPSMA-DM1) that reached Phase I clinical trials for prostate cancer and an aCCR2 antibody that was in Phase II clinical trials for autoimmune diseases (Millenium Pharma). He received his PhD in Biology at Binghamton University followed by 3 years of post-doctoral studies at Boston University School of Medicine investigating proteases in Alzheimer disease. |
|
|
Marcus |
|
Semones |
|
CSO |
Erez Capital |
https://proventainternational.com/wp-content/uploads/2022/05/avatar.jpg |
|
|
|
Michal |
|
Preminger |
|
Stratetic Advisor |
Jefferson Life Sciences |
https://proventainternational.com/wp-content/uploads/2025/03/Michal-Preminger.jpg |
|
|
|
Tomasz |
|
H. Zastawny, |
|
Chief Executive Officer |
Armora Biosciences |
https://proventainternational.com/wp-content/uploads/2025/02/Tomasz-H.-Zastawny.jpg |
Tomasz H. Zastawny, PhD, DSc is a veteran life sciences executive with over 25 years of leadership in drug development, corporate strategy, and commercialization. Currently CEO of Armora Biosciences, he holds Board positions at PVR Clinical Research, TrialHer (AI-MedTech), and Auxilius Pharma.Dr. Zastawny specializes in capital-efficient strategies that accelerate assets from discovery to exit. He led the clinical operations and development teams responsible for the global marketing authorizations of TAZVERIK® (Epizyme), FOTIVDA® (Aveo Oncology), and Alluminox™ (Rakuten Medical). Today, he advises companies on leveraging AI, virtual models, and value-added regulatory pathways to de-risk development and maximize investor ROI. |
|
|
Robert |
|
Gabriel |
|
Board Member, Managing Partner |
Ashur Capital |
https://proventainternational.com/wp-content/uploads/2025/04/Robert-Gabriel-2.jpg |
Dr. Robert Gabriel has broad experience in technology and business development. He founded Genesis Aromatique and led the company for over 15 years. Prior to that, Gabriel led technology and business development initiatives at Unilever, Gillette, Clorox, and Rhone-Poulenc. In his current role as Ashur Capital’s managing partner and board member, Dr. Gabriel provides strategic direction for asset allocation and capital deployment. He is also an investor and board member at Clear Protocol, a digital health startup. Dr. Gabriel earned a Ph.D. from the University of Illinois and an MBA from the Wharton School of Business. Dr. Gabriel is married and has 4 sons. |
|
|
Stephan |
|
Krause |
|
Executive Director, Cell Therapy Global Quality |
Bristol Myers Squibb |
https://proventainternational.com/wp-content/uploads/2025/02/Stephan-Krause.jpg |
Dr. Stephan Krause is the Executive Director, Cell Therapy Global Quality at Bristol Myers Squibb. He is a recognized industry leader for advancing best practices for analytical method lifecycle steps to support acceleration of product development. Stephan is currently chair of PDA’s ATMP Advisory Board (since 2021), chair of the ANSI task force for standardizing analytical lifecycle steps and conditions (since 2022), and chair of TR56 R1 Annex ATMP for phase-appropriate QMS (since 2024). He has won numerous innovation, advocating, and publication awards. Based on his high-impact publications and advocacy, Stephan was invited multiple times in recent years to present an industry perspective to the FDA and other regulatory agencies to support the implementation of ICH Q2(R2), Q12, and Q14. |
|
|
Robert |
|
Gabriel |
|
Board Member, Managing Partner |
Ashur Capital |
https://proventainternational.com/wp-content/uploads/2025/04/Robert-Gabriel-2.jpg |
Dr. Robert Gabriel has broad experience in technology and business development. He founded Genesis Aromatique and led the company for over 15 years. Prior to that, Gabriel led technology and business development initiatives at Unilever, Gillette, Clorox, and Rhone-Poulenc. In his current role as Ashur Capital’s managing partner and board member, Dr. Gabriel provides strategic direction for asset allocation and capital deployment. He is also an investor and board member at Clear Protocol, a digital health startup. Dr. Gabriel earned a Ph.D. from the University of Illinois and an MBA from the Wharton School of Business. Dr. Gabriel is married and has 4 sons. |
Le Meridien Cambridge
Payment Securely powered by stripe
